Compassionate Use of Beraprost Sodium 314d Modified Release (BPS-314d-MR) for Three Patients With Pulmonary Arterial Hypertension (PAH)
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Beraprost (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Expanded access
- 18 Jun 2019 Status changed from active, no longer recruiting to completed.
- 31 Jan 2018 Planned end date changed from 1 Dec 2017 to 1 Dec 2019.
- 31 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.